166 related articles for article (PubMed ID: 24140611)
1. Decanoic acid-modified glycol chitosan hydrogels containing tightly adsorbed palmityl-acylated exendin-4 as a long-acting sustained-release anti-diabetic system.
Lee C; Choi JS; Kim I; Byeon HJ; Kim TH; Oh KT; Lee ES; Lee KC; Youn YS
Acta Biomater; 2014 Feb; 10(2):812-20. PubMed ID: 24140611
[TBL] [Abstract][Full Text] [Related]
2. Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system.
Lee J; Lee C; Kim TH; Lee ES; Shin BS; Chi SC; Park ES; Lee KC; Youn YS
J Control Release; 2012 Aug; 161(3):728-34. PubMed ID: 22634071
[TBL] [Abstract][Full Text] [Related]
3. Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia.
Lee J; Lee C; Kim I; Moon HR; Kim TH; Oh KT; Lee ES; Lee KC; Youn YS
Int J Pharm; 2012 Mar; 424(1-2):50-7. PubMed ID: 22226877
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice.
Lee J; Lee C; Kim TH; Chi SC; Moon HR; Oh KT; Lee ES; Lee KC; Youn YS
Regul Pept; 2012 Aug; 177(1-3):68-72. PubMed ID: 22561689
[TBL] [Abstract][Full Text] [Related]
5. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes.
Kim H; Park H; Lee J; Kim TH; Lee ES; Oh KT; Lee KC; Youn YS
Biomaterials; 2011 Feb; 32(6):1685-93. PubMed ID: 21126761
[TBL] [Abstract][Full Text] [Related]
6. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
Lee C; Choi JS; Kim I; Oh KT; Lee ES; Park ES; Lee KC; Youn YS
Int J Nanomedicine; 2013; 8():2975-83. PubMed ID: 23976850
[TBL] [Abstract][Full Text] [Related]
7. Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.
Son S; Lim SM; Chae SY; Kim K; Park EJ; Lee KC; Na DH
Int J Pharm; 2015 Nov; 495(1):81-86. PubMed ID: 26325318
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
Kim I; Kim TH; Ma K; Lee ES; Kim D; Oh KT; Lee DH; Lee KC; Youn YS
Bioconjug Chem; 2010 Aug; 21(8):1513-9. PubMed ID: 20715855
[TBL] [Abstract][Full Text] [Related]
9. Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics.
Kim TH; Jiang HH; Lee S; Youn YS; Park CW; Byun Y; Chen X; Lee KC
Bioconjug Chem; 2011 Apr; 22(4):625-32. PubMed ID: 21401109
[TBL] [Abstract][Full Text] [Related]
10. Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.
Kim H; Lee J; Kim TH; Lee ES; Oh KT; Lee DH; Park ES; Bae YH; Lee KC; Youn YS
Pharm Res; 2011 Aug; 28(8):2008-19. PubMed ID: 21472489
[TBL] [Abstract][Full Text] [Related]
11. Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.
Kim TH; Jiang HH; Lim SM; Youn YS; Choi KY; Lee S; Chen X; Byun Y; Lee KC
Bioconjug Chem; 2012 Nov; 23(11):2214-20. PubMed ID: 23116483
[TBL] [Abstract][Full Text] [Related]
12. A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action.
Kim I; Kim TH; Ma K; Park ES; Oh KT; Lee ES; Lee KC; Youn YS
Regul Pept; 2011 Apr; 167(2-3):239-45. PubMed ID: 21329731
[TBL] [Abstract][Full Text] [Related]
13. Exendin-4 improves the oral glucose tolerance in diabetic rats: pancreas regeneration, better function of pancreatic islets, or impaired glucose uptake?
Strauss A; Moskalenko V; Chodnevskaja I; Timm S; Thiede A; Otto C; Ulrichs K
Transplant Proc; 2008 Mar; 40(2):533-5. PubMed ID: 18374122
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
[TBL] [Abstract][Full Text] [Related]
15. The role of clusterin on pancreatic beta cell regeneration after exendin-4 treatment in neonatal streptozotocin administrated rats.
Kaya-Dagistanli F; Ozturk M
Acta Histochem; 2013 Jul; 115(6):577-86. PubMed ID: 23351716
[TBL] [Abstract][Full Text] [Related]
16. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
Roan JN; Cheng HN; Young CC; Lee CJ; Yeh ML; Luo CY; Tsai YS; Lam CF
J Surg Res; 2017 Feb; 208():93-103. PubMed ID: 27993221
[TBL] [Abstract][Full Text] [Related]
17. Formulation and evaluation of an in situ gel forming system for controlled delivery of triptorelin acetate.
Abashzadeh Sh; Dinarvand R; Sharifzadeh M; Hassanzadeh G; Amini M; Atyabi F
Eur J Pharm Sci; 2011 Nov; 44(4):514-21. PubMed ID: 21946260
[TBL] [Abstract][Full Text] [Related]
18. Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin.
Peng Q; Sun X; Gong T; Wu CY; Zhang T; Tan J; Zhang ZR
Acta Biomater; 2013 Feb; 9(2):5063-9. PubMed ID: 23036950
[TBL] [Abstract][Full Text] [Related]
19. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery.
Gordon S; Saupe A; McBurney W; Rades T; Hook S
J Pharm Pharmacol; 2008 Dec; 60(12):1591-600. PubMed ID: 19000363
[TBL] [Abstract][Full Text] [Related]
20. A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel.
Li K; Yu L; Liu X; Chen C; Chen Q; Ding J
Biomaterials; 2013 Apr; 34(11):2834-42. PubMed ID: 23352120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]